



Memo to: Healthcare Personnel
From: Alverno Clinical Laboratories, General Laboratory
Subject: **New Test Starting December 9, 2008– anti-Cyclic Citrullinated Peptide (anti-CCP)**

We are pleased to announce a new service for our healthcare providers, anti-Cyclic Citrullinated Peptide (anti-CCP) IgG/IgA testing.

According to American College of Rheumatology, approximately 95% of patients with a positive CCP test will develop Rheumatoid Arthritis in the future.

Anti-CCP is a marker used in the evaluation of patients suspected of having Rheumatoid Arthritis (RA). Previously, Rheumatoid Factor (RF) was the most widely used marker for RA. The sensitivity and specificity for RF is ~60-90% and 70-80% respectively. RF may be found in patients with other rheumatic diseases. The sensitivity and specificity for anti-CCP is ~60-80% and 90-98% respectively. **Therefore, anti-CCP has equivalent sensitivity and increased specificity for RA over RF.** The highest specificity is achieved by testing for both anti-CCP and RF. Starting December 9th, Alverno Clinical Laboratories will offer testing for both RF and anti-CCP for the evaluation of Rheumatoid Arthritis.

These tests are FDA approved and manufactured by Inova.

SPECIMEN COLLECTION

Specimen sources: 1 ml serum

Specimen stability: 8 hrs at Room Temperature, 48 hrs refrigerated, >48 hours frozen

Unacceptable Conditions: Hemolyzed

Soft order code: CYCTP

Alverno Clinical Laboratories
2434 Interstate Plaza Drive
Hammond, IN 46324
(219) 989-3700